MY185334A - Glucagon derivatives with improved stability - Google Patents

Glucagon derivatives with improved stability

Info

Publication number
MY185334A
MY185334A MYPI2017000967A MYPI2017000967A MY185334A MY 185334 A MY185334 A MY 185334A MY PI2017000967 A MYPI2017000967 A MY PI2017000967A MY PI2017000967 A MYPI2017000967 A MY PI2017000967A MY 185334 A MY185334 A MY 185334A
Authority
MY
Malaysia
Prior art keywords
glucagon derivative
present
glucagon
improved stability
glucagon derivatives
Prior art date
Application number
MYPI2017000967A
Other languages
English (en)
Inventor
Jung Kuk Kim
Jong Min Lee
Sang Yun Kim
Sung Min Bae
Sung Youb Jung
Se Chang Kwon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MY185334A publication Critical patent/MY185334A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MYPI2017000967A 2014-12-30 2015-12-30 Glucagon derivatives with improved stability MY185334A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140193800 2014-12-30
PCT/KR2015/014422 WO2016108586A1 (ko) 2014-12-30 2015-12-30 안정성이 증가된 글루카곤 유도체

Publications (1)

Publication Number Publication Date
MY185334A true MY185334A (en) 2021-05-06

Family

ID=56284642

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017000967A MY185334A (en) 2014-12-30 2015-12-30 Glucagon derivatives with improved stability

Country Status (28)

Country Link
US (1) US11135271B2 (show.php)
EP (2) EP3241841A4 (show.php)
JP (2) JP6797122B2 (show.php)
KR (1) KR102291020B1 (show.php)
CN (1) CN107636009B (show.php)
AR (1) AR103322A1 (show.php)
AU (1) AU2015372818A1 (show.php)
CL (1) CL2017001718A1 (show.php)
CO (1) CO2017006308A2 (show.php)
CR (1) CR20170293A (show.php)
DO (1) DOP2017000156A (show.php)
EA (1) EA035527B1 (show.php)
EC (1) ECSP17040923A (show.php)
ES (1) ES2976562T3 (show.php)
GT (1) GT201700150A (show.php)
HK (1) HK1248713A1 (show.php)
IL (2) IL253206B (show.php)
MA (1) MA40709B1 (show.php)
MX (1) MX2017008569A (show.php)
MY (1) MY185334A (show.php)
PE (2) PE20230304A1 (show.php)
PH (1) PH12017501222B1 (show.php)
SG (1) SG11201705376SA (show.php)
TN (1) TN2017000271A1 (show.php)
TW (1) TW201639878A (show.php)
UA (1) UA126960C2 (show.php)
WO (1) WO2016108586A1 (show.php)
ZA (1) ZA201705015B (show.php)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230304A1 (es) * 2014-12-30 2023-02-13 Hanmi Pharm Ind Co Ltd Derivados de glucagon como agentes hipoglucemicos y antiobesidad
FI3322437T3 (fi) * 2015-06-30 2024-02-20 Hanmi Pharmaceutical Co Ltd Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
TWI877582B (zh) 2015-12-31 2025-03-21 南韓商韓美藥品股份有限公司 三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑
SG11201811697SA (en) * 2016-06-29 2019-01-30 Hanmi Pharmaceutical Co Ltd Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
CN110545849A (zh) 2017-02-03 2019-12-06 韩美药品株式会社 具有增加的持续性的生理活性物质的缀合物及其应用
EP3708661A4 (en) * 2017-12-22 2021-12-01 Hanmi Pharm. Co., Ltd. THERAPEUTIC ENZYMFUSION PROTEIN WITH A NEW STRUCTURE AND ITS USE
KR20200134213A (ko) * 2018-01-23 2020-12-01 엑스에리스 파머수티클스, 인크. 소 용량의 안정한 글루카곤을 사용한 베리아트릭 후 저혈당증의 치료
US20220064248A1 (en) 2018-12-21 2022-03-03 HANMl PHARM. CO., LTD Pharmaceutical composition including insulin and glucagon
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
WO2021235907A1 (ko) 2020-05-22 2021-11-25 한미약품 주식회사 글루카곤 유도체의 지속형 결합체의 액상 제제
MX2023000698A (es) 2020-07-15 2023-04-18 Hanmi Pharmaceutical Co Ltd Uso terapeutico del derivado de glucagon o conjugado del mismo para enfermedades hepaticas.
AU2022254588A1 (en) 2021-04-09 2023-09-21 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating chronic renal disease including glucagon derivative
KR20230095666A (ko) 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도
CN115536739B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
EP1411968B1 (en) 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
HRP20050683A2 (en) 2003-03-19 2006-07-31 Eli Lilly And Company Polyethylene glycol linked glp-1 compounds
CN1723220A (zh) 2003-11-13 2006-01-18 韩美药品工业株式会社 含有免疫球蛋白fc区作为载体的药物组合物
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
EP2574624A1 (en) 2006-04-20 2013-04-03 Amgen Inc. GLP-1 compounds
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
WO2008086086A2 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP2111414B1 (en) * 2007-02-15 2014-07-02 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
KR20100049032A (ko) 2007-06-19 2010-05-11 오츠카 가가쿠 가부시키가이샤 당사슬 부가 ｇｌｐ―１ 펩티드
JP5476304B2 (ja) * 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
CN104447980A (zh) * 2008-06-17 2015-03-25 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
AU2009274425B2 (en) 2008-06-17 2014-05-15 Indiana University Research And Technology Corporation GIP-based mixed agonists for treatment of metabolic disorders and obesity
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
CN102459325B (zh) 2009-06-16 2015-03-25 印第安纳大学科技研究有限公司 胃抑胜肽受体活化的胰高血糖素化合物
WO2011006497A1 (en) 2009-07-13 2011-01-20 Zealand Pharma A/S Acylated glucagon analogues
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
US20130157953A1 (en) 2010-01-20 2013-06-20 Zealand Pharma A/S Treatment of cardiac conditions
US20130035285A1 (en) * 2010-03-26 2013-02-07 Novo Nordisk A/S Novel glucagon analogues
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CA2821766A1 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
CN103732617A (zh) 2011-05-18 2014-04-16 梅德瑞斯糖尿病有限责任公司 用于胰岛素抵抗的改进的肽医药
CA3064214C (en) 2011-06-10 2023-03-07 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
MX353402B (es) * 2011-06-17 2018-01-11 Hanmi Science Co Ltd Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo.
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
EP2780031B1 (en) * 2011-11-17 2018-03-07 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
KR20150023013A (ko) 2012-06-21 2015-03-04 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 수용체 활성을 나타내는 글루카곤 유사체
AU2013277372B2 (en) 2012-06-21 2018-03-29 Indiana University Research And Technology Corporation Analogs of glucagon exhibiting GIP receptor activity
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
SG10201602801YA (en) 2012-11-06 2016-05-30 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
US10005817B2 (en) 2012-11-20 2018-06-26 Eumederis Pharmaceuticals, Inc. Peptide pharmaceuticals
KR102213907B1 (ko) 2012-11-20 2021-02-09 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 약제
CA2895875A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 derivatives
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP3033355A1 (en) 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
PE20230304A1 (es) 2014-12-30 2023-02-13 Hanmi Pharm Ind Co Ltd Derivados de glucagon como agentes hipoglucemicos y antiobesidad
FI3322437T3 (fi) 2015-06-30 2024-02-20 Hanmi Pharmaceutical Co Ltd Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
TWI877582B (zh) 2015-12-31 2025-03-21 南韓商韓美藥品股份有限公司 三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑

Also Published As

Publication number Publication date
PH12017501222B1 (en) 2024-07-03
ZA201705015B (en) 2018-04-25
SG11201705376SA (en) 2017-08-30
HK1248713A1 (en) 2018-10-19
EA035527B1 (ru) 2020-06-30
CA2972748A1 (en) 2016-07-07
UA126960C2 (uk) 2023-03-01
IL281375B (en) 2021-10-31
ECSP17040923A (es) 2017-12-01
EA201791333A1 (ru) 2017-12-29
PH12017501222A1 (en) 2018-01-15
US20170360892A1 (en) 2017-12-21
EP3575314B1 (en) 2024-02-14
KR20160082482A (ko) 2016-07-08
JP2018504901A (ja) 2018-02-22
EP3575314A3 (en) 2020-01-22
EP3241841A1 (en) 2017-11-08
EP3575314C0 (en) 2024-02-14
CN107636009B (zh) 2021-04-16
TN2017000271A1 (en) 2018-10-19
AU2015372818A1 (en) 2017-07-27
JP2020188819A (ja) 2020-11-26
WO2016108586A1 (ko) 2016-07-07
IL253206A0 (en) 2017-08-31
EP3575314A2 (en) 2019-12-04
CO2017006308A2 (es) 2017-09-29
MA40709A1 (fr) 2017-12-29
MX2017008569A (es) 2017-10-20
CN107636009A (zh) 2018-01-26
JP7079301B2 (ja) 2022-06-01
IL281375A (en) 2021-04-29
TW201639878A (zh) 2016-11-16
GT201700150A (es) 2018-12-12
MA40709B1 (fr) 2019-07-31
CL2017001718A1 (es) 2018-01-12
NZ770767A (en) 2024-04-26
KR102291020B1 (ko) 2021-08-20
BR112017014205A2 (pt) 2018-03-06
AR103322A1 (es) 2017-05-03
JP6797122B2 (ja) 2020-12-09
CR20170293A (es) 2017-11-03
PE20171154A1 (es) 2017-08-16
US11135271B2 (en) 2021-10-05
ES2976562T3 (es) 2024-08-05
NZ733464A (en) 2024-01-26
DOP2017000156A (es) 2017-10-15
IL253206B (en) 2021-10-31
EP3241841A4 (en) 2018-10-17
PE20230304A1 (es) 2023-02-13

Similar Documents

Publication Publication Date Title
PH12017501222B1 (en) Glucagon derivatives with improved stability
WO2015106269A8 (en) Rapid action insulin formulations and pharmaceutical delivery systems
SG11201811697SA (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
NZ733670A (en) Insulin glargine/lixisenatide fixed ratio formulation
EA033298B1 (ru) Комбинированная лекарственная форма тезофензина и метопролола
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
EA033446B1 (ru) Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта
BR112017025000A2 (pt) tratamento de hipoglicemia pós-bariátrica com exendina (9-39)
PH12017501205A1 (en) Glucagon derivatives
MY192813A (en) Aqueous formulation comprising paracetamol and ibuprofen
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2015008555A (es) Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
EA201592058A1 (ru) Применение ландиолола гидрохлорида в длительном лечении тахиаритмии
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2020013211A (es) Composicion farmaceutica para el tratamiento de mal de parkinson.
MX380088B (es) Uso terapéutico de una solución oftálmica acuosa estéril.
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
TR201903234T4 (tr) Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti.
SG10201809418VA (en) New administration routes of insulin, insulin analogs or derivatives of insulin
PL414785A1 (pl) Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną
HK1228762A1 (en) Rapid action insulin formulations and pharmaceutical delivery systems
MY173606A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease